Literature DB >> 10970014

Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials.

P R Williamson1, A G Marson, C Tudur, J L Hutton, D Chadwick.   

Abstract

Meta-analysis may be based on either aggregate data or individual patient data (IPD). Three reasons why IPD are desirable for the meta-analysis of anti-epileptic drug (AED) monotherapy trials are: (1) to undertake a more complete analysis of time-to-event outcomes; (2) to investigate the interaction between AED and type of epilepsy; and (3) to undertake re-analysis of the trial to obtain results for all relevant outcomes. We demonstrate that IPD meta-analysis is possible in AED research. Problems arose from missing data at four levels: (1) unknown trials; (2) known trials but no IPD supplied; (3) known trials but missing outcome data for some individuals within trials; and (4) known trials but missing covariate data for some individuals within trials. Empirical evidence of the reliability of meta-analyses based on aggregate rather than individual patient data is still lacking. Examples of other benefits such projects may bring include improvements to the design of a new trial in the area, in terms of the sample size considerations, the definition of outcomes and data collection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970014     DOI: 10.1046/j.1365-2753.2000.00236.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  14 in total

Review 1.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 2.  Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nolan; Catrin Tudur Smith; Jennifer Weston; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

3.  Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Anthony G Marson; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-07-18

4.  Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Authors:  J D Adachi; C C Kennedy; A Papaioannou; G Ioannidis; W D Leslie; V Walker
Journal:  Osteoporos Int       Date:  2009-03-11       Impact factor: 4.507

5.  High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.

Authors:  Jing Wang; Qiguo Zhang; Rongfu Zhou; Bing Chen; Jian Ouyang
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

6.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

7.  Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Anthony G Marson; Jennifer Weston; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2018-08-09

Review 8.  Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Jennifer Weston; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

Review 9.  Individual participant data meta-analyses compared with meta-analyses based on aggregate data.

Authors:  Catrin Tudur Smith; Maura Marcucci; Sarah J Nolan; Alfonso Iorio; Maria Sudell; Richard Riley; Maroeska M Rovers; Paula R Williamson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-06

10.  Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Anthony G Marson; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.